Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma.[9][10] It is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and also inhibits AXL and RET.[8][7] It was discovered and developed by Exelixis Inc.
In November 2012, cabozantinib in its capsule formulation was approved by the US Food and Drug Administration (FDA) under the name Cometriq for treating people with medullary thyroid cancer.[13][14] The capsule form was approved in the European Union for the same purpose in 2014.[11] In April 2016, the FDA granted approval for marketing the tablet formulation (Cabometyx) as a second line treatment for kidney cancer[15][16] and the same was approved in the European Union in September of that year.[12] The brands Cometriq and Cabometyx have different formulations and are not interchangeable.[17]
^"Cabozantinib Use During Pregnancy". Drugs.com. 30 March 2020. Retrieved 23 September 2020.
^"Cabometyx (Ipsen Pty Ltd)". Therapeutic Goods Administration (TGA). 13 January 2023. Retrieved 9 April 2023.
Cabozantinib, sold under the brand names Cometriq and Cabometyx among others, is an anti-cancer medication used to treat medullary thyroid cancer, renal...
partnered its lead cancer drug candidate, XL-184 (which would become called cabozantinib) and another cancer candidate, XL-281, with Bristol Myers Squibb; BMS...
surgery. Cabozantinib, trade name Cometriq, was granted marketing approval (November 2012) by the U.S. FDA for this indication. Cabozantinib which is...
Institute. His work has led to the establishment of several novel drugs (cabozantinib, avelumab, pazopanib and others including combinations) and prognostic...
spasticity in children aged two years and older. In 2016, Ipsen licensed cabozantinib from Exelixis, which received marketing authorization the same year for...
cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib. Selpercatinib can cause serious side effects including...
that it is due to the decreased absorption of abacavir by orlistat. Cabozantinib: Drugs from the MRP2 inhibitor (Multidrug resistance-associated protein...
that possess a broad range of targets along with RET. These included cabozantinib, lenvatinib, sunitinib and alectinib. Since they were not designed to...
vascular endothelial growth factor receptor 2 (VEGFR-2). c-Met inhibitors Cabozantinib, a similar molecule and kinase inhibitor with FDA approval VEGFR inhibitor...
Global Information
